EP4700791A3 - Multi-omik-beurteilung - Google Patents

Multi-omik-beurteilung

Info

Publication number
EP4700791A3
EP4700791A3 EP25225298.6A EP25225298A EP4700791A3 EP 4700791 A3 EP4700791 A3 EP 4700791A3 EP 25225298 A EP25225298 A EP 25225298A EP 4700791 A3 EP4700791 A3 EP 4700791A3
Authority
EP
European Patent Office
Prior art keywords
methods
omic
assessment
diseases
disease states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25225298.6A
Other languages
English (en)
French (fr)
Other versions
EP4700791A2 (de
Inventor
Philip Ma
Bruce Wilcox
Francois Collin
Chinmay BELTHANGADY
Manway LIU
Manoj KHADKA
Mi Yang
John Blume
JR. Robert S. LANGER
Ehdieh KHALEDIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prognomiq Inc
Original Assignee
Prognomiq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prognomiq Inc filed Critical Prognomiq Inc
Priority claimed from PCT/US2022/022654 external-priority patent/WO2022212583A1/en
Publication of EP4700791A2 publication Critical patent/EP4700791A2/de
Publication of EP4700791A3 publication Critical patent/EP4700791A3/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
EP25225298.6A 2021-03-31 2022-03-30 Multi-omik-beurteilung Pending EP4700791A3 (de)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202163168634P 2021-03-31 2021-03-31
US202163168594P 2021-03-31 2021-03-31
US202163183816P 2021-05-04 2021-05-04
US202163183844P 2021-05-04 2021-05-04
US202163183852P 2021-05-04 2021-05-04
US202163183829P 2021-05-04 2021-05-04
US202163184498P 2021-05-05 2021-05-05
US202163228533P 2021-08-02 2021-08-02
US202163228543P 2021-08-02 2021-08-02
US202163229232P 2021-08-04 2021-08-04
US202163229242P 2021-08-04 2021-08-04
US202163256482P 2021-10-15 2021-10-15
US202163278637P 2021-11-12 2021-11-12
US202163288825P 2021-12-13 2021-12-13
US202163288827P 2021-12-13 2021-12-13
US202263312455P 2022-02-22 2022-02-22
US202263322149P 2022-03-21 2022-03-21
EP22782140.2A EP4315366A4 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung
PCT/US2022/022654 WO2022212583A1 (en) 2021-03-31 2022-03-30 Multi-omic assessment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP22782140.2A Division EP4315366A4 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung

Publications (2)

Publication Number Publication Date
EP4700791A2 EP4700791A2 (de) 2026-02-25
EP4700791A3 true EP4700791A3 (de) 2026-04-29

Family

ID=81653211

Family Applications (3)

Application Number Title Priority Date Filing Date
EP25225299.4A Pending EP4700792A3 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung
EP22782140.2A Pending EP4315366A4 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung
EP25225298.6A Pending EP4700791A3 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP25225299.4A Pending EP4700792A3 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung
EP22782140.2A Pending EP4315366A4 (de) 2021-03-31 2022-03-30 Multi-omik-beurteilung

Country Status (7)

Country Link
US (4) US20230187028A1 (de)
EP (3) EP4700792A3 (de)
JP (1) JP2024516522A (de)
CN (1) CN121726086A (de)
AU (1) AU2022249074A1 (de)
CA (1) CA3210376A1 (de)
GB (1) GB2607184B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113237A1 (en) * 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
AU2022341187A1 (en) 2021-09-13 2024-03-21 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
CN117056840B (zh) * 2023-07-07 2025-06-20 福建师范大学 一种血清sers光谱数据的异常检测方法
WO2025096340A1 (en) * 2023-10-30 2025-05-08 Somalogic Operating Co., Inc. Systems and methods for development of proteomic models
WO2025145100A1 (en) * 2023-12-27 2025-07-03 PrognomIQ, Inc. Multi-omics assessment
WO2025179149A1 (en) * 2024-02-22 2025-08-28 Toby, Inc. Training and use of machine-learning models for predicting biological conditions using volatile organic compounds
CN119475061A (zh) * 2025-01-15 2025-02-18 国科大杭州高等研究院 生物分子冠拉曼光谱信号数据的分析识别系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985819A (zh) * 2010-07-09 2013-03-20 私募蛋白质体公司 肺癌生物标记及其用途
US20180068083A1 (en) * 2014-12-08 2018-03-08 20/20 Gene Systems, Inc. Methods and machine learning systems for predicting the likelihood or risk of having cancer
WO2019200410A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples
WO2019209888A1 (en) * 2018-04-23 2019-10-31 Seer, Inc. Systems and methods for complex biomolecule sampling and biomarker discovery
CA3126990A1 (en) * 2019-02-14 2020-08-20 Maneesh Jain Methods and systems for determining a pregnancy-related state of a subject

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063683A1 (en) * 1999-04-20 2000-10-26 Target Discovery, Inc. Polypeptide fingerprinting methods, metabolic profiling, and bioinformatics database
WO2005036180A1 (en) * 2003-10-08 2005-04-21 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Analysis methods using biomarkers concentrated with biomarkers attractant molecules
TW200640596A (en) 2005-01-14 2006-12-01 Cabot Corp Production of metal nanoparticles
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US8748352B2 (en) * 2011-08-16 2014-06-10 Battelle Memorial Institute Peptide and protein biomarkers for type 1 diabetes mellitus
AU2012358246B2 (en) * 2011-12-21 2018-01-25 Integrated Diagnostics, Inc. Methods for diagnosis of lung cancer
EP2935628B1 (de) * 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Zusammensetzungen und verfahren für aptamer-screening
US20220328134A1 (en) * 2021-03-31 2022-10-13 PrognomIQ, Inc. Multi-omic assessment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985819A (zh) * 2010-07-09 2013-03-20 私募蛋白质体公司 肺癌生物标记及其用途
US20180068083A1 (en) * 2014-12-08 2018-03-08 20/20 Gene Systems, Inc. Methods and machine learning systems for predicting the likelihood or risk of having cancer
WO2019200410A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples
WO2019209888A1 (en) * 2018-04-23 2019-10-31 Seer, Inc. Systems and methods for complex biomolecule sampling and biomarker discovery
CA3126990A1 (en) * 2019-02-14 2020-08-20 Maneesh Jain Methods and systems for determining a pregnancy-related state of a subject

Also Published As

Publication number Publication date
EP4315366A4 (de) 2024-10-09
AU2022249074A1 (en) 2023-09-21
GB2607184B (en) 2024-07-17
EP4700792A3 (de) 2026-04-29
US20260066051A1 (en) 2026-03-05
JP2024516522A (ja) 2024-04-16
GB202205374D0 (en) 2022-05-25
US20230187028A1 (en) 2023-06-15
EP4315366A1 (de) 2024-02-07
US20260066052A1 (en) 2026-03-05
CN121726086A (zh) 2026-03-24
EP4700791A2 (de) 2026-02-25
US20230223111A1 (en) 2023-07-13
GB2607184A (en) 2022-11-30
CA3210376A1 (en) 2022-10-06
EP4700792A2 (de) 2026-02-25

Similar Documents

Publication Publication Date Title
WO2023240046A3 (en) Multi-omics assessment
EP4700792A3 (de) Multi-omik-beurteilung
US20240112752A1 (en) Methods and systems for annotating genomic data
O’Sullivan et al. A whole mitochondria analysis of the Tyrolean Iceman’s leather provides insights into the animal sources of Copper Age clothing
Denti et al. Spatial multiomics of lipids, N-glycans, and tryptic peptides on a single FFPE tissue section
Park et al. Parallel reaction monitoring-mass spectrometry (PRM-MS)-based targeted proteomic surrogates for intrinsic subtypes in breast cancer: comparative analysis with immunohistochemical phenotypes
EP2560006A3 (de) Biomarker von Prostatakrebs und Verfahren zu deren Verwendung
Cannataro et al. Neutral theory and the somatic evolution of cancer
CN112292697A (zh) 用于生物样品的多分析物测定的机器学习实施方式
Li et al. Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor
WO2005017646A3 (en) System, software and methods for biomarker identification
Faulkner et al. Proteogenomics: emergence and promise
WO2005010492A3 (en) Classification of disease states using mass spectrometry data
US20190121937A1 (en) Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations
Libes et al. Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens
Edsjö et al. High‐throughput molecular assays for inclusion in personalised oncology trials–State‐of‐the‐art and beyond
Borden et al. Neoantigen fitness model predicts lower immune recognition of cutaneous squamous cell carcinomas than actinic keratoses
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
Doebar et al. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing
Doyle et al. Studying cancer genomics through next-generation DNA sequencing and bioinformatics
Simon Applications of tissue microarray technology
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
Porter Molecular markers of tumor initiation and progression
Zhang et al. GPnotebook: A pan-cancer glycoproteomic database and toolkit for analysis of protein glycosylation changes associated with cancer phenotypes
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 4315366

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: G16H0050200000

Ipc: G16H0050700000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0010931_4700791/2026

Effective date: 20260325

RIC1 Information provided on ipc code assigned before grant

Ipc: G16H 30/40 20180101ALI20260323BHEP

Ipc: G16H 50/70 20180101AFI20260323BHEP

Ipc: G16B 40/20 20190101ALI20260323BHEP

Ipc: G16H 20/40 20180101ALI20260323BHEP

Ipc: G16H 30/20 20180101ALI20260323BHEP

Ipc: G16B 20/00 20190101ALI20260323BHEP

Ipc: G16H 20/10 20180101ALI20260323BHEP

Ipc: G16H 10/40 20180101ALI20260323BHEP

Ipc: G16H 50/20 20180101ALI20260323BHEP